Met Life Investment Management, LLC Protagonist Therapeutics, Inc Transaction History
Met Life Investment Management, LLC
- $18.1 Billion
- Q1 2025
A detailed history of Met Life Investment Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 34,790 shares of PTGX stock, worth $1.6 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
34,790
Previous 35,798
2.82%
Holding current value
$1.6 Million
Previous $1.38 Million
21.8%
% of portfolio
0.01%
Previous 0.01%
Shares
32 transactions
Others Institutions Holding PTGX
# of Institutions
299Shares Held
61.3MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$281 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$265 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$263 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$197 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$138 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.26B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...